An FDA-approved Treatment for the Leading Cause of Dry Eye
Meibomian Gland Dysfunction (MGD) is thought to be the leading cause of dry eye disease. MGD occurs when the meibomian glands in the upper and lower eyelids do not secrete enough oil when you blink. This lack of oil causes the normal tear layer on the eye to evaporate too quickly, leaving the eyes dry and easily irritated.
LipiFlow® is an FDA-approved treatment available at the Dean McGee Eye Institute for patients with MGD. LipiFlow® treats MGD by warming and massaging the inside of the eyelids to restore healthy oil production.
12 minutes for up to 12 months of Relief
Patients are evaluated to determine whether they suffer from MGD using LipiView®, an imaging device specifically designed to view the meibomian glands. If it is determined a patient is a candidate for LipiFlow®, treatment can be administered the very same day. Treatment takes approximately 12 minutes per eye and provides relief that can last up to 12 months.
LipiView® and LipiFlow® are not covered by Medicare or other insurance plans. The out-of-pocket expense for an evaluation is $50 plus a patient’s standard insurance copay or deductible for an office visit. The out-of-pocket expense for the LipiFlow® treatment is $470 per eye.